Monitor for initiation of the planned US clinical study in pancreatic cancer pain and any updates on FDA regulatory pathway, which are the next material catalysts for the stock.
Price Chart
Executive Summary
Autonomix Medical announced the issuance of a Canadian patent (No. 3,183,802) covering its catheter-based transvascular intervention platform, expanding its global IP portfolio to 112 issued or pending applications. The patent protects technologies for accessing tissue beyond the vessel wall, multi-site electrophysiological sensing, and closed-loop adaptive therapy delivery. This is a routine IP milestone for a pre-revenue medical device company and does not change the fundamental risk profile or near-term revenue outlook.
Key Facts
- Canadian Patent No. 3,183,802 issued by CIPO, titled 'Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall'
- Autonomix's global IP portfolio now includes 112 issued or pending patent applications worldwide
- Corresponding patents previously issued in the United States and Europe
- Patent covers catheter-based transvascular tools, multi-site electrophysiological sensing, closed-loop control, and methods for assessing procedural completion
- Patent expirations extend into the late 2030s
- Technology is investigational and not yet cleared for marketing in the US
Financial Impact
No financial impact — pre-revenue company with no marketed products; patent issuance does not generate revenue or change cash runway
Risk Factors
- Technology remains investigational with no FDA clearance or marketed products
- Pre-revenue company with no near-term revenue visibility
- Patent issuance does not guarantee commercial success or market adoption
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373785 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $3.01 | awaiting T+20 | — | $2.10 (−30.23%) |
Oct 2, 2026 24d ago | Press Release | $3.78 | awaiting T+20 | — | $2.10 (−44.44%) |
Sep 16, 2026 5w ago | 8-K | $4.12 $3.01 | ▼ −26.94% | ▼ −30.12% | $2.10 (−49.03%) |
Sep 16, 2026 5w ago | EFFECT | $4.12 $3.01 | ▲ +26.94% | ▲ +30.12% | $2.10 (+49.03%) |
Sep 11, 2026 6w ago | 424B5 | $4.33 $3.10 | ▲ +28.41% | ▲ +30.67% | $2.10 (+51.50%) |
Sep 4, 2026 7w ago | S-3 | $4.58 $3.47 | ▲ +24.24% | ▲ +25.95% | $2.10 (+54.15%) |
Aug 26, 2026 8w ago | 8-K | $5.63 $4.07 | ▼ −27.71% | ▼ −27.20% | $2.10 (−62.70%) |
Aug 5, 2026 11w ago | EFFECT | $12.10 $4.50 | ▼ −62.81% | ▼ −62.21% | $2.10 (−82.64%) |
Jul 28, 2026 12w ago | 8-K | $2.75 $7.19 | ▲ +161.45% | ▲ +158.07% | $2.10 (−23.64%) |
Jul 15, 2026 14w ago | 8-K | $4.92 $6.86 | ▼ −39.43% | ▼ −35.81% | $2.10 (+57.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers